Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases

Table 3 Comparative analysis of patients with autoimmune hepatitis concomitant with nonalcoholic fatty liver disease and patients with nonalcoholic fatty liver disease with autoimmune phenomena

Variable	Patients with AIH concomitant with NAFLD (n = 61)	Patients with NAFLD with autoimmune phenomena (n = 34)	P value
Age, yr	52.05 ± 11.11	43.68 ± 13.71	< 0.001
Male sex, n (%)	13 (21.3)	6 (17.6)
BMI, kg/m2	24.21 ± 3.10	24.65 ± 2.02
Laboratory
AST, U/L	55.03 ± 47.31	50.03 ± 29.26
ALT, U/L	66.62 ± 74.94	86.01 ± 62.59
AKP, U/L	63.00 (45.00, 84.00)	75.00 (54.00, 87.00)
GGT, U/L	49.27 ± 32.24	69.26 ± 44.07	< 0.05
Total bilirubin, mg/dL	10.20 (8.60, 14.10)	10.25 (7.40, 13.67)
Direct bilirubin, mg/dL	4.20 (3.20, 5.00)	3.70 (2.92, 4.65)
IgG	15.60 ± 4.57	13.81 ± 2.67	< 0.05
IgM	1.18 ± 0.45	1.28 ± 0.57
Histological steatosis stage, n (%)
S1	39 (63.9)	8 (23.5)
S2	17 (27.9)	10 (29.4)
S3	5 (8.2)	16 (47.1)
Histological fibrosis stage, n (%)
F1	17 (27.9)	6 (17.6)
F2	22 (36.1)	14 (41.2)
F3	16 (26.2)	11 (32.4)
F4	6 (9.8)	3 (8.8)
CAP, dB/m	272.57 ± 44.39	293.41 ± 51.04	< 0.05
LSM in total, kPa	9.34 ± 7.14	6.49 ± 2.44	< 0.05
In steatosis S1	9.19 ± 8.11	5.28 ± 1.88	< 0.05
In steatosis S2	7.80 ± 3.47	6.31 ± 2.18
In steatosis S3	15.76 ± 6.25	7.20 ± 2.69	< 0.01

Distributions are expressed as the mean ± SD or median [interquartile range] or number (percentage). AKP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CAP: Controlled attenuation parameter; GGT: Gamma-glutamyl transferase; LSM: Liver stiffness measurement; AIH: Autoimmune hepatitis; NAFLD: Nonalcoholic fatty liver.